RecruitingNot Applicable

Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children

South Korea6,000 participantsStarted 2012-01

Plain-language summary

The purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (Eutropin Inj./Eutropin plus Inj.) treatment with GHD (Growth Hormone Deficiency), TS (Turner Syndrome),CRF (Chronic Renal Failure), SGA (Small for Gestational Age), and ISS (Idiopathic Short Stature).

Who can participate

Age range2 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * short stature children aged 2 years or more * children with GHD,TS, CRF, SGA or ISS * written informed consent from the person, person's parent or legal guardian

What they're measuring

Safety measure : adverse event

Timeframe: up to 2 years after epiphyseal closure

Trial details

NCT IDNCT01604395

SponsorLG Chem

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2032-12-31

Contact for this trial

YoungHwan Jang

82-2-6924-3158 younghj@lgls.com

View on ClinicalTrials.gov More Growth Hormone Deficiency trials